Ata Male Testosterone Replacement Indications

---
name: ata-male-testosterone-replacement-indications
description: Recommends testosterone replacement for adult males with central hypogonadism and no contraindications to prevent anemia related to T deficiency; reduce fat mass; and improve BMD, libido, sexual function, energy levels, sense of well-being, and muscle mass and strength. Triggers include consideration of testosterone replacement in males with central hypogonadism (e.g., low serum testosterone with symptoms of deficiency).
---

# Indicate testosterone replacement for adult males with central hypogonadism

## STEP 1 — Gather Information
Collect morning total testosterone (before 10 AM after overnight fast), LH, FSH, and prolactin to confirm central hypogonadism (low testosterone with low/normal LH/FSH). Assess for contraindications: prostate or breast cancer, severe untreated sleep apnea, hematocrit >54%, PSA >4 ng/mL (or age-specific), and desire for fertility without discussing alternatives.

## STEP 2 — Rule In / Rule Out
If total testosterone is below the laboratory lower limit with LH/FSH low or normal (indicating central hypogonadism) AND no contraindications are present → Rule in as eligible for testosterone replacement; otherwise → Rule out (do not initiate replacement).

## STEP 3 — Classify or Stratify
Stratify by symptom burden: presence of anemia (Hb <13 g/dL), low BMD (T-score <-1.5), low libido, low energy, decreased muscle mass, or increased fat mass. If any of these are present → high priority for replacement; if none are present → still consider replacement for preventive benefit per guideline.

## STEP 4 — Decide
Offer testosterone replacement (e.g., transdermal gel 50 mg daily or intramuscular ester 75–100 mg every 1–2 weeks) targeting physiologic total testosterone levels (approximately 300–1000 ng/dL). Schedule follow‑up labs (testosterone, hematocrit, PSA) and symptom review at 3–6 months.

## Clinical Guardrails / Mimics / Pitfalls
Do not treat if prostate or breast cancer is present, severe untreated sleep apnea, hematocrit >54%, or if the patient desires fertility without discussing alternatives (e.g., gonadotropins). Avoid in uncontrolled heart failure or recent myocardial infarction/stroke. Monitor for erythrocytosis and worsening sleep apnea.

## Concrete Clinical Example
A 45‑year‑old male post‑resection of a pituitary macroadenoma has morning testosterone 200 ng/dL, LH 1.5 IU/L, FSH 2.0 IU/L, normal prolactin, hemoglobin 12.8 g/dL (mild anemia), lumbar spine T‑score –2.0, reports low libido and fatigue. No contraindications identified. Initiate testosterone gel 50 mg daily, re‑check testosterone and hematocrit in 3 months, assess symptoms and adjust dose as needed.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118